Home > Insider Trading > Filing (0001567619-20-018008)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1799448	Aligos Therapeutics Inc.	ALGS	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1687880	Versant Venture Capital Vi, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104		No	No	Yes	No
1765253	Versant Vantage I, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-10-20	2,145,991	$0.00	2,145,991	No	4	C	Direct
Common Stock	Acquisiton	2020-10-20	198,839	$0.00	2,344,830	No	4	C	Direct
Common Stock	Acquisiton	2020-10-20	85,065	$0.00	2,429,895	No	4	C	Direct
Common Stock	Acquisiton	2020-10-20	463,959	$0.00	463,959	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-10-20	198,485	$0.00	662,444	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-10-20	200,000	$15.00	862,444	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2020-10-20	2,145,991	$0.00	2,145,991	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2020-10-20	198,839	$0.00	198,839	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2020-10-20	463,959	$0.00	463,959	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-10-20	85,065	$0.00	85,065	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-10-20	198,485	$0.00	198,485	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Indirect
No	4	C	Direct
No	4	C	Indirect

Footnotes

Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.
These securities are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP. Thomas Woiwode Ph.D. is a managing director of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. A Form 4 is being filed separately by Dr. Woiwode in his capacity as a Director of the Issuer.
These securities are held of record by by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP, L.P. ("VV I GP") is the general partner of VV I, and Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the general partner of VV I GP. Thomas Woiwode Ph.D. is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I and disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. A Form 4 is being filed separately by Dr. Woiwode in his capacity as a Director of the issuer.